LIver Cancer
Conditions
Interventions
Experimental Group:TACE+IMRT+Apatinib
Control Group:TACE+IMRT
Sponsors
Yan An Hospital of Kunming City
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Obtain informed consent forms from the patients; 2. Eligible patients are pathologically diagnosed with hepatocellular carcinoma; 3. Child-Pugh score A/B; 4. Aged 18 to 75 years; No surgical condition or unwilling to accept surgical operation; 5. KPS score= 70, and the expected survival time is greater than 3 months; 6. Previous routine examination of peripheral blood should meet the following conditions (neutrophils count >2000/mm3, platelet count > 80,000 /mm3); 7. No surgical medical diseases; The blood clotting time is regular; 8. ECOG PS score: 0-2 points; 9. Patients with detectable and measurable lesions; 10. Integrity of follow-up data.
Exclusion criteria
Exclusion criteria: 1. Portal vein and any vascular invasion; 2. Tumor load>50%; 3. Patients with hypertension and the blood pressure cannot be reduced down to normal range by antihypertensive drugs (Systolic pressure > 140 mmHg, diastolic pressure > 90 mmHg);4. Patients with level II or above myocardial ischemia or myocardial infarction, poor control arrhythmia (Including QTC interval in male=450ms, QTC interval in female=470ms) 5. Combined HIV-infected patients; 6. Patients with kidney failure or renal function disorder, blood or peritoneal dialysis is required; 7. Multiple factors that could influence oral drug administration (eg. Inability to swallow, Chronic diarrhea and intestinal obstruction, Under several particular circumstances, drug administration and absorption could be significantly influenced); 8. In past 6 months, patient has a history of gastrointestinal bleeding or clear tendency of gastrointestinal bleeding, eg. Patients with esophageal varices with bleeding risk, local active ulcer lesions and defecate occult blood= (++) are prohibited into group, gastroscopy is necessarily demanded for patients with defecate occult blood= (+); 9. Serious active clinical infection (>2 level, NCI-CTCAE version 4.0), HBV and HCV infectious are excluded 10. Urinary protein detected by urine routine test= ++ or 24-hour urinary protein quantity is proved >1.0g; 11. Pregnant or lactating women, patients with fertility are unwilling or unable to take effective contraceptive measures; 12. Patients accepted major surgeries within the first 4 weeks before this clinical trial (eg.ntrathoracic, intraperitoneal or pelvic cavity), or patients have not yet completely recovered from this kind of surgeries).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public ContactKe-Hua Yuan
Yan An Hospital of Kunming City
Outcome results
None listed